Drug intelligence / Profile preview

pembrolizumab + abiraterone + prednisone

Development stage: Unknown
Lead developer: Merck
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

Pembrolizumab + abiraterone + prednisone is a combination therapy evaluated primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who are chemotherapy-naïve. Pembrolizumab is a monoclonal antibody checkpoint inhibitor targeting programmed death 1 (PD-1), thereby enhancing anti-tumor immune response. Abiraterone is a small molecule inhibitor of CYP17A1, leading to decreased androgen biosynthesis, while prednisone is a synthetic glucocorticoid used to mitigate side effects of abiraterone and provide additional anti-cancer and anti-inflammatory effects. This combination has demonstrated antitumor activity and acceptable safety in clinical studies.

Brand names: Keytruda + Zytiga + prednisone
Other names: pembrolizumab plus abiraterone plus prednisone

Targets

GR (Glucocorticoid receptor)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on pembrolizumab + abiraterone + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pembrolizumab + abiraterone + prednisone.

Explore the full profile